Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$33.3B
134M shares
52-week range
$197.81 – $495.55
17% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
P/S (TTM)
7.2
EV / FCF (TTM)
62.8
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam's commercial RNAi therapeutic products include Onpattro and Amvuttra (for hATTR amyloidosis), Givlaari (for acute hepatic porphyria), and Oxlumo (for primary hyperoxaluria type 1), all developed and commercialized by Alnylam. Plus, Leqvio (for hypercholesterolemia) and Qfitlia (for hemophilia A or B), which are being commercialized by Alnylam's partners, Novartis and Sanofi, respectively. It also has several clinical programs across various therapeutic areas, including cardio-metabolic diseases, neuroscience, and hematology.
www.alnylam.comNo one on the platform currently holds ALNY.
| Institution | Shares | Reported |
|---|---|---|
| Bridgewater Associatesas of 2026-03-31 | 106,592 | $35.3M |
No one on the platform has traded ALNY yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | 118.7% | — | — | — | ||
| Rev. Growth % | 65.2% | 49.8% | ||||
| Profit Margin % | 8.4% | -47.6% | -324.8% | |||
| Free Cash Flow Margin % | 12.5% | -26.2% | -271.2% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is +11.0% on the P/E track.
At today's price, your expected annual return is +19.3% on the P/E track.
At today's price, your expected annual return is +27.4% on the P/E track.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $5.5B | +45.6% | $6.67 | $6.21–$7.16 | 37.4× | 15 |
| 2027 | $6.9B | +26.9% | $10.08 | $7.17–$11.44 | 24.8× | 15 |
| 2028 | $8.3B | +19.6% | $12.51 | $-2.21–$18.90 | 20.0× | 17 |
| 2029 | $9.3B | +12.5% | $14.37 | $12.54–$16.64 | 17.4× | 12 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 5 of the last 8 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-07-30 | $1.63 | $1.21 | -25.8% |
| 2026-04-30 | $0.87 | $1.51 | +73.2% |
| 2026-02-12 | $1.16 | $0.82 | -29.3% |
| 2025-10-30 | $0.56 | $1.84 | +228.0% |
| 2025-07-31 | $-0.54 | $-0.51 | +6.2% |
| 2025-05-01 | $-0.89 | $-0.44 | +50.6% |
| 2025-02-13 | $-0.62 | $-0.65 | -4.8% |
| 2024-10-31 | $-0.92 |
| $-0.87 |
| +5.1% |
| $76.6B |
| — |
| CORCencora, Inc. | $326.23 | +1.45% | $63.5B | — |
| EWEdwards Lifesciences Corporation | $85.52 | +1.36% | $49.2B | — |
Source: Financial Modeling Prep · peers by sector/industry
Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.
$ALNY Down largely because it wasn't included in S& P quarterly rebalance?
View on StockTwits ↗
$ALNY | Alnylam Pharmaceuticals, Inc. (Healthcare / RNAi Therapeutics 🧬🔬⚡️) $ALNY is commercializing RNA interference (RNAi) drugs (Amvuttra, Onpattro) to "silence" disease-causing genes before bad proteins form. The company is profitable with surging quarter-over-quarter revenue driven by Amvuttra's rapid market adoption. Technically, $ALNY is rebounding off its $205.48 double-bottom support, currently consolidating right under $269.94–$272.00 resistance. A firm break above $272.00 triggers a squeeze toward the 200-day moving average at $291.10 and macro resistance at $339.41. Key Technical Levels: • Confirmation Trigger: $272.00 🚀 • Pivot Support: $240.00 🐂 • Overhead Target 1: $291.10 🎯 • Overhead Target 2: $339.41 💰 • Downside Risk Level: $205.48 🐻 • Stop Loss: $235.00 🔴 Flow & Market Bias: Structure: 1W Trendline Reversal / Base Support Recovery Bias: Bullish above $240.00 #ALNY #stockmarket #technicalanalysis #swingtrading #hovdid
View on StockTwits ↗$ALNY up 20% and we are just getting started look at the BUY volume.
View on StockTwits ↗$ALNY Gee South Carolina , must have had ICE take out all the MAGA morons !!!
View on StockTwits ↗
$ALNY or maybe not… pretty clear either way that media is owned / controlled by institutions
View on StockTwits ↗
$ALNY ..we,ve seen the bottom... not getting in this cheap again....
View on StockTwits ↗
$ALNY Alnylam announces new data at ESC Congress on AMVUTTRA Alnylam Pharmaceuticals announced new data at the European Society of Cardiology, ESC, Congress 2026 demonstrating the strength of RNAi-powered silencing for cardiovascular disease. The findings further reinforce the clinical profile of AMVUTTRA across transthyretin amyloidosis, ATTR, patient populations, treatment settings, and manifestations of disease. Additionally, the data expand the potential application of RNAi to uncontrolled hypertension, the world's leading cause of cardiovascular disease. "With the power of our RNAi therapeutics platform, we have the potential to make a transformational impact on cardiovascular care," said Pushkal Garg, M.D., Chief Research and Development Officer at Alnylam. "The data presented at ESC demonstrate the consistency of clinical outcomes achieved by RNAi-powered TTR silencing, reinforcing our conviction in AMVUTTRA as a first-line treatment option for ATTR-CM. With zilebesiran, we have the potential to extend the precision and durability of RNAi to uncontrolled hypertension. Together, these programs reflect our ambition to change the course of cardiovascular disease for patients with high unmet need."
View on StockTwits ↗$ALNY The work of John, when CEO, and associates makes nah sayers , run with their tales between their legs , in other words , fcuk off ! Move over AstraZeneca …there is a new guy in town , and his name IS NOT , TAK . @drizz @telomerase , nor bugle boy , @RaphaelRapoport
View on StockTwits ↗$ALNY update: up 6% since alert heres updated chart inside day - consolidation, RSI has a ton of gas in the tank.. Paitence the buys will come #hovdid
View on StockTwits ↗
IONS, AZN Stocks Fall On Full Data From Failed Cardiomyopathy Trial — Jefferies Sees Neutral To Negative Readthrough To ALNY $ALNY $IONS $AZN https://stocktwits.com/news/equity/markets/ions-azn-stocks-fall-on-full-data-from-failed-cardiomyopathy-trial-jefferies-sees-neutral-to-negative-readthrough-to-alny/cZYAZyuRJA6
View on StockTwits ↗
$ALNY Almost 1,200 call option of $260 traded today for 09/18/26 expiry. I expect price move up on Monday after new data this wekend.
View on StockTwits ↗
$IONS, $AZN Eplontersen (Wainua) failed to reduce heart events in 1,432 ATTR-CM patients. Results raise questions on silencer-plus-stabilizer use and for $ALNY’s pipeline. https://notreload.xyz/xy/alnylam-faces-read-through-after-wainua-miss/
View on StockTwits ↗$ALNY appears the friendship between Stat News and Alnylam has expired. Maybe the friendship was actually with bond rollers and institutions the whole time? @skeezbag
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.